In pan-cancer analysis (Fig. 7D,E), CT83 high expression is correlated with worse RFS in kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). Here, CT83 is linked to lung adenocarcinoma.